Vyome Holdings: A Derisked Clinical Asset Trading at a Fraction of Fair Value
An investment analysis of Vyome Holdings ($HIND), a clinical-stage biotech with a Phase 3-ready asset for malignant fungating wounds trading at 22% of conservative fair value.